[ad_1]
Subscribe to the epidemic newsletter
We send you what you need to know about the epidemic every day of the week. Sign up and take care of each other!
In its statement on Friday, the World Health Organization (WHO) no longer explicitly recommends the use of remdesivir in the care of patients with coronavirus. They argue that there is insufficient evidence that a drug originally developed to treat Ebola would improve the chances of survival and recovery for those infected. The recommendation was made by a 33-member committee.
In mid-October, the WHO released the results of a study of 11,000 coronavirus patients in 30 countries, which found that remdesivir had no significant effect on coronavirus patients.
Previous research in the United States has shown that remdesivir reduces recovery time by a third in patients with severe COVID-19, although it doesn’t really help patients with milder symptoms. Gilead, the American pharmaceutical company that developed the drug, argued in October that the WHO research results had not yet been published in a major medical journal, so the research results and the data on which it was based they had not been verified.
Remdesivir is already manufactured in Hungary and is used to treat the infected. Semmelweis University cited a more reliable study published in the New England Journal, which found that patients treated with remdesivir recovered faster than those who received placebo and had a lower death rate.
[ad_2]
